Article ID Journal Published Year Pages File Type
3197804 Journal of Allergy and Clinical Immunology 2013 11 Pages PDF
Abstract
These data demonstrate the 5-year durability of the benefits of BT with regard to both asthma control (based on maintained reduction in severe exacerbations and ED visits for respiratory symptoms) and safety. BT has become an important addition to our treatment armamentarium and should be considered for patients with severe persistent asthma who remain symptomatic despite taking inhaled corticosteroids and long-acting β2-agonists.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , , , , , , , , , , , , ,